Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. (Q40113425)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Thomas Nelius

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Tobias Klatte

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Werner de Riese

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

30 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

International Urology and Nephrology

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

97-104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)--delayed response and flare phenomenon should be considered

1 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11255-007-9221-Y

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

21 January 2018

1 reference

12 December 2020

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

1 reference

12 December 2020

Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

Cancer statistics, 2005

1 reference

12 December 2020

Cancer statistics, 2004

1 reference

12 December 2020

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

12 December 2020

Prostate cancer schemes for androgen escape

1 reference

12 December 2020

Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation

1 reference

12 December 2020

Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells

1 reference

12 December 2020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

12 December 2020

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

12 December 2020

The development of androgen-independent prostate cancer

1 reference

12 December 2020

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

12 December 2020

Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel

1 reference

12 December 2020

Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma

1 reference

12 December 2020

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

12 December 2020

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist

1 reference

12 December 2020

Androgen receptor (AR) coregulators: an overview

1 reference

12 December 2020

Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.

1 reference

12 December 2020

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

1 reference

12 December 2020

Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.

1 reference

12 December 2020

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Analysis and sorting of prostate cancer cell types by flow cytometry

1 reference

12 December 2020

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

12 December 2020

Intratumoral nuclear morphologic heterogeneity in prostate cancer

1 reference

12 December 2020

10.1007/S11255-007-9221-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17602304%20AND%20SRC:MED&resulttype=core&format=json

release_cjvwrnruxvholgzuykx44hriru

1 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cjvwrnruxvholgzuykx44hriru

24 November 2022

mapped directly with Wikidata item

1 reference